From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy. (2012)

Peer-Reviewed Study · Krafts K; Hempelmann E; Skórska-Stania A · March 13, 2012

Krafts K et al., 2012-03-13: Review tracing antimalarial drug development from methylene blue research to chloroquine – the real basis of the methylene-blue/antimalarial comparison, and it concerns chloroquine, not hydroxychloroquine.

In this article, we trace the origins of an antimalarial therapy from the discovery of the nature of the malarial parasite through the development of chloroquine.

Krafts K et al., 2012-03-13: Review tracing antimalarial drug development from methylene blue research to chloroquine – the real basis of the methylene-blue/antimalarial comparison, and it concerns chloroquine, not hydroxychloroquine. C13 Krafts 2012. Study type: narrative historical review. Country: USA/Switzerland/Poland (authors at UMDNJ, University of Zurich, Jagiellonian University). Dose: N/A. Funder/conflicts: not stated in the record. What it supports: that methylene blue's antimalarial activity (Ehrlich, 1891) is in the lineage of chloroquine's development. What it does not support: any claim that methylene blue and hydroxychloroquine are interchangeable, and it does not use the phrase 'parent molecule' – hydroxychloroquine is a hydroxylated analogue of chloroquine, a 4-aminoquinoline, not a phenothiazine. Study type: review.